Majority of Newborns With Spinal Muscular Atrophy Treated With Genentech’s Evrysdi Sit Independently After 1 Year Treatment

 

• RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least 5 seconds after 1 year of Evrysdi treatment — without treatment these babies would never be able to sit
• All babies were able to swallow and feed orally and none required permanent ventilation
• Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globally

https://www.biospace.com/article/releases/majority-of-newborn-babies-with-spinal-muscular-atrophy-sma-treated-with-genentech-s-evrysdi-able-to-sit-independently-after-1-year-of-treatment/